Your browser doesn't support javascript.
loading
Clinical Practice Guideline for Blood-based Circulating Tumor DNA Assays.
Lee, Jee-Soo; Cho, Eun Hye; Kim, Boram; Hong, Jinyoung; Kim, Young-Gon; Kim, Yoonjung; Jang, Ja-Hyun; Lee, Seung-Tae; Kong, Sun-Young; Lee, Woochang; Shin, Saeam; Song, Eun Young.
Afiliación
  • Lee JS; Department of Laboratory Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
  • Cho EH; Department of Laboratory Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kim B; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Hong J; Samkwang Medical Laboratories, Seoul, Korea.
  • Kim YG; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kim Y; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Jang JH; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Lee ST; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Kong SY; Dxome Co. Ltd., Seongnam, Korea.
  • Lee W; Department of Laboratory Medicine, National Cancer Center, Goyang, Korea.
  • Shin S; Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Song EY; Department of Laboratory Medicine, Yonsei University College of Medicine, Seoul, Korea.
Ann Lab Med ; 44(3): 195-209, 2024 May 01.
Article en En | MEDLINE | ID: mdl-38221747
ABSTRACT
Circulating tumor DNA (ctDNA) has emerged as a promising tool for various clinical applications, including early diagnosis, therapeutic target identification, treatment response monitoring, prognosis evaluation, and minimal residual disease detection. Consequently, ctDNA assays have been incorporated into clinical practice. In this review, we offer an in-depth exploration of the clinical implementation of ctDNA assays. Notably, we examined existing evidence related to pre-analytical procedures, analytical components in current technologies, and result interpretation and reporting processes. The primary objective of this guidelines is to provide recommendations for the clinical utilization of ctDNA assays.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN Tumoral Circulante Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Ann Lab Med Año: 2024 Tipo del documento: Article Pais de publicación: Corea del Sur
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: ADN Tumoral Circulante Tipo de estudio: Guideline / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Ann Lab Med Año: 2024 Tipo del documento: Article Pais de publicación: Corea del Sur